Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Eliza Vakana

Eliza Vakana is a scientist, PhD graduate of Northwestern University, Robert H Lurie Comprehensive Cancer Center and division of hematology/oncology, Northwestern University Medical School Chicago, IL 60611.

Contact Info

Email:
elizavakana@gmail.com

Recent stories

  • Micrograph of acute myeloid leukaemia (AML)

    Current treatments and future targeted treatments for acute myeloid leukaemiaSubscription

    7 MAR 2016

    While the initial therapy for acute myeloid leukaemia (AML) treatment is relatively standardised, the high incidence of refractory/relapsed disease remains a great challenge. Progress has been made in understanding the pathophysiology of both initial and recurrent disease phases, leading to rigorous pre-clinical studies to identify and selectively target cellular pathways that promote leukaemogenesis. In this article, we discuss the ongoing efforts in overcoming relapsed disease, through a l

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.